道氏技術(300409.SZ):與湖南培森簽署《戰略合作協議》併成立合資公司
格隆匯11月10日丨道氏技術(300409.SZ)公佈,近日,公司與湖南培森電子科技有限公司(以下簡稱“湖南培森”)簽署了《戰略合作協議》併成立合資公司,各方基於互惠互利和相互促進原則,建立戰略合作關係,通過設立合資公司進行深度合作,以公司科研與生產數據驗證劉傑教授團隊的非馮·諾依曼架構的分子動力學計算系統“NVNMD”的應用技術,並推動人工智能技術在道氏技術產品科研、生產製造等環節上的應用,以提高道氏技術的研發、生產與經營水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.